Processa Pharmaceuticals, Inc. (PCSA)
NASDAQ: PCSA · IEX Real-Time Price · USD
1.530
-0.050 (-3.16%)
Apr 22, 2024, 4:00 PM EDT - Market closed
Processa Pharmaceuticals Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for PCSA stock has a target of 4.00, which predicts an increase of 161.44% from the current stock price of 1.53.
Analyst Consensus: Buy
* Price targets were last updated on Mar 6, 2024.
Analyst Ratings
The average analyst rating for PCSA stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 3 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 4 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Benchmark | Benchmark | Buy Reiterates $4 | Buy | Reiterates | $4 | +161.44% | Mar 6, 2024 |
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 17, 2023 |
| Benchmark | Benchmark | Buy Maintains $180 → $80 | Buy | Maintains | $180 → $80 | +5,128.76% | Apr 4, 2023 |
| Oppenheimer | Oppenheimer | Buy Maintains $100 → $60 | Buy | Maintains | $100 → $60 | +3,821.57% | Apr 3, 2023 |
| Maxim Group | Maxim Group | Strong Buy Maintains $180 → $100 | Strong Buy | Maintains | $180 → $100 | +6,435.95% | Jan 12, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-7.14
from -8.48
EPS Next Year
-6.12
from -7.14
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | n/a | 44.9M |
| Avg | n/a | n/a | n/a | n/a | 43.7M |
| Low | n/a | n/a | n/a | n/a | 42.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -7.35 | -6.30 | -6.51 | -0.28 | 0.66 |
| Avg | -7.14 | -6.12 | -6.32 | -0.28 | 0.64 |
| Low | -6.86 | -5.88 | -6.08 | -0.26 | 0.62 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.